CIDARA THERAPEUTICS INC (CDTX) Stock Analyst Ratings
USA - NASDAQ:CDTX - US1717572069 - Common Stock
93.12 USD
-3.04 (-3.16%)
92.0229 USD
-1.1 (-1.18%)
ChartMill assigns a Buy % Consensus number of 85% to CDTX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 134.3. This target is 44.22% above the current price.
CDTX was analyzed by 13 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about CDTX.
In the previous month the buy percentage consensus was at a similar level.
CDTX was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-16 | Morgan Stanley | Initiate | Overweight |
| 2025-10-10 | JP Morgan | Initiate | Overweight |
| 2025-10-09 | WBB Securities | Maintains | Strong Buy -> Strong Buy |
| 2025-10-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-03 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-09-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-25 | Guggenheim | Maintains | Buy -> Buy |
| 2025-09-24 | WBB Securities | Reiterate | Strong Buy -> Strong Buy |
| 2025-09-24 | Needham | Maintains | Buy -> Buy |
| 2025-09-22 | WBB Securities | Maintains | Strong Buy -> Strong Buy |
| 2025-08-08 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-08-08 | Needham | Maintains | Buy -> Buy |
| 2025-08-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-06-30 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-06-24 | Guggenheim | Maintains | Buy -> Buy |
| 2025-06-24 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-06-23 | WBB Securities | Reiterate | Strong Buy -> Strong Buy |
| 2025-06-23 | Needham | Maintains | Buy -> Buy |
| 2025-06-10 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-06-04 | Needham | Maintains | Buy -> Buy |
| 2025-06-02 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-05-27 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-05-23 | Needham | Reiterate | Buy -> Buy |
| 2025-05-23 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-16 | Guggenheim | Maintains | Buy -> Buy |
| 2025-05-09 | Guggenheim | Maintains | Buy -> Buy |
| 2025-05-09 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-04-29 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-04-10 | Needham | Reiterate | Buy -> Buy |
CIDARA THERAPEUTICS INC / CDTX FAQ
What is the average price target for CIDARA THERAPEUTICS INC (CDTX) stock?
13 analysts have analysed CDTX and the average price target is 134.3 USD. This implies a price increase of 44.22% is expected in the next year compared to the current price of 93.12.
How do analysts rate CIDARA THERAPEUTICS INC (CDTX)?
The consensus rating for CIDARA THERAPEUTICS INC (CDTX) is 84.6154 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed CIDARA THERAPEUTICS INC (CDTX)?
The number of analysts covering CIDARA THERAPEUTICS INC (CDTX) is 13.